Features and clinical significance of rtA181 mutation of hepatitis B virus

doi:10.3877/cma.j.issn.1674-1358.2017.02.005

Abstract

Abstract:

Patients with chronic hepatitis B (CHB) could be successfully treated using nucleos(t)ide analogues (NAs), but drug resistance mutations of hepatitis B virus (HBV) frequently arise which seriously affect the clinical efficacy. RtA181 mutation is a cross-resistant mutance, which affects viral replication and the secretion of HBsAg, it could also increase the risk of hepatoma occurrence. This article reviewed the above points.

Key words: Hepatitis B virus, rtA181 mutation, Drug resistance

Ting Pang, Huichun Xing. Features and clinical significance of rtA181 mutation of hepatitis B virus[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 125-128.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.02.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I02/125

Figures/Tables 1

References 28

1	Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues[J]. Gastroenterology,2009,137(5):1593-1608.
2	Rhee SY, Margeridon-Thermet S, Nguyen M H, et al. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery[J]. Antiviral Res,2010,88(3):269-275.
3	Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants[J]. World J Hepatol,2015,7(8):1086-1096.
4	李晓东，蒋丽红，李梵, 等. 乙型肝炎病毒发生rtA181T突变的临床特点与意义分析[J]. 中华肝脏病杂志,2015,23(1):23-27.
5	姬粉芝，王磊，杨保华, 等. rtA181位点突变乙型肝炎病毒感染患者的临床特点及个体化再治疗效果[J]. 中华肝脏病杂志,2012,20(4):280-284.
6	Jiang SW, Yao LP, Hu AR, et al. Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates[J]. World J Gastroenterol,2014,20(45):17100-17106.
7	刘海霞，李娟，朱跃科, 等. 核苷类似物抗病毒治疗失败的慢性乙型肝炎患者基因型耐药分析[J]. 临床荟萃,2011,26(16):1385-1387.
8	恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识: 2015年更新[J]. 临床肝胆病杂志,2016,32(1):32-39.
9	刘晓彦，徐纯琼，张栩, 等. 未进行抗病毒治疗慢性乙型肝炎81例预存耐药分析[J]. 临床荟萃,2013,28(8):887-888.
10	Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure[J]. J Hepatol,2008,48(5):747-755.
11	Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents[J]. Antivir Ther,2007,12(3):355-362.
12	Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus[J]. J Clin Virol,2002,25(2):97-106.
13	Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy[J]. Antivir Ther,2010,15(3):471-475.
14	Ahn SH, Park YK, Park ES, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol,2014,88(12):6805-6818.
15	Zhou LY, Chen EQ, Wang ML, et al. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems[J]. Sci Rep,2016,6:39260.
16	Rodriguez C, Chevaliez S, Bensadoun P, et al. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing[J]. Hepatology,2013,58(3):890-901.
17	Yuen LK, Ayres A, Littlejohn M, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B[J]. Antiviral Res,2007,75(1):64-74.
18	Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172^* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound[J]. Hepatology,2008,48(1):88-98.
19	李新艳，尹有宽，张继明, 等. 阿德福韦耐药乙型肝炎病毒毒株生物学特性的研究[J]. 中华传染病杂志,2009(8):478-483.
20	Dai J, Chen EQ, Bai L, et al. Biological characteristics of the rtA181T/sW172^* mutant strain of Hepatitis B virus in animal model[J]. Virol J,2012,9:280.
21	王江华，李俊强，蒋栋, 等. 乙型肝炎病毒rtA181V/T和rtN236T变异ADV耐药株表达质粒的构建及其病毒学特征[J]. 中华检验医学杂志,2007,30(9):1035-1039.
22	Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine[J]. J Hepatol,2008,48(4):540-547.
23	杨松，邢卉春，王琦, 等. 慢性乙型肝炎患者阿德福韦酯治疗出现病毒学突破的耐药分析[J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(3):94-97.
24	Kekule AS, Lauer U, Meyer M, et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator[J]. Nature,1990,343(6257):457-461.
25	Lauer U, Weiss L, Hofschneider PH, et al. The hepatitis B virus pre-S/S(t) transactivator is generated by 3’ truncations within a defined region of the S gene[J]. J Virol,1992,66(9):5284-5289.
26	Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant[J]. Antivir Ther,2008,13(7):875-879.
27	Lai MW, Huang SF, Hsu CW, et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy[J]. Antivir Ther,2009,14(2):249-261.
28	Yeh CT, Chen T, Hsu CW, et al. Emergence of the rtA181T/sW172^* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC cancer,2011,11:398.

rt变异	相应HBsAg变异
rtF166L	sF158Y
rtI169T	sF161L
rtV173L	sE164D
rtA181V	sL173F
rtS184G	sL/V176G
rtS202I	sV194F
rtA204V	sI195M
rtM204I	sW196S/L
rtA181T	sW172*
rtV191I	sW182*
rtM204I	sW196^*
rtV207I	sW199^*
rtL180M	无氨基酸改变
rtA194T	无氨基酸改变
rtN236T	无氨基酸改变

rt变异	相应HBsAg变异
rtF166L	sF158Y
rtI169T	sF161L
rtV173L	sE164D
rtA181V	sL173F
rtS184G	sL/V176G
rtS202I	sV194F
rtA204V	sI195M
rtM204I	sW196S/L
rtA181T	sW172*
rtV191I	sW182*
rtM204I	sW196^*
rtV207I	sW199^*
rtL180M	无氨基酸改变
rtA194T	无氨基酸改变
rtN236T	无氨基酸改变

[1]	Ling Wei, Hui Li, Yi Chen. Current research status on colonization or infection and mother-to-child transmission of extended-spectrum β-lactamase-producing Enterobacteriaceae in pregnant and post-partum women [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 517-521.
[2]	Jiajin Tu, Wuqiang Liao, Jinjing Liu, Zhipeng Tu, Yuangui Mao. Risk factors and prognosis analysis of Acinetobacter baumannii bloodstream infection in patients with severe burns [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 491-497.
[3]	Wei Li, Junqiao Mo. Genotype identification and drug resistance analysis of respiratory tract drug-resistant Haemophilus influenzae in children for the choice of antibiotic treatment [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 315-323.
[4]	Xiaoman Zhang, Xiaoqiu Ma, Zhengju Xu, Chunyu Zhang, Caiting He. Effect of drug-resistant mutations in reverse transcriptase region of hepatitis B virus on the level of serum hepatitis B surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 324-332.
[5]	Yingying Wang, Ping Xie. Risk factors of liver injury in patients with hepatitis B virus infection and pulmonary tuberculosis and predictive model construction [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(04): 267-273.
[6]	Haijin Zhang, Zengguo Wang, Huijun Cai, Bingtong Zhao. Distribution and drug resistance of pathogenic bacteria in neonates from 2020 to 2022 in Xi’an Children’s Hospital [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(04): 222-229.
[7]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[8]	Changqing Cao, Xinyan Guo, Yuan Gao, Cun Zhang, Haili Tang, Dong Fan, Xiaojun Yang, Song Zhang, Huadong Zhao. Research progress on the involvement of tumor microenvironment in mediating trastuzumab resistance in HER2-positive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 90-95.
[9]	Xuexue Lei, Ying Yu, Hongyan Li. Clinical research of multimodal prehabilitation optimization program in patients with hepatitis B virus-related liver cirrhosis awaiting liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 158-163.
[10]	Xiaodan Wang, Yuan Wang, Xiangyu Cui, Xiaolei Ren. Analysis of pathogenic bacteria resistance of drug and high risk factors of death in urogenic sepsis after endoscopic surgery for upper urinary tract stones [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 611-615.
[11]	Shudian Chen, Yun Liang, Yuan Liao, Yang Wang. Prognostic value of complement C3 in patients with HBV-related acute-on-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 562-566.
[12]	Paerhati Nadina, Chen Huang. The role of cancer-associated fibroblasts in cancer progression and chemotherapy resistance of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 241-247.
[13]	Jingjing Li, Lei Zhai, Haiping Zhao, Bo Zheng. Polycystic kidney disease complicated with cystic infection caused by multi-drug resistant Klebsiella pneumoniae: a case report and literature review [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 920-923.
[14]	Chong Chen, Ranran You, Min Wang, Haojie Zhou. Blood safety analysis of single-HBsAg-reagent(+)/NAT(-) blood donors [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 95-98,104.
[15]	Huiping Wei, Yingming Guo, Guirong Liu, Zongyou Wu, Qiuqing Weng. Application value of superoxide dismutase test in hepatitis B virus related liver disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 21-26.

Please choose a citation manager

Content to export